Compare Quest Diagnostics Inc (DGX) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NetEase Inc — how do they compare? Quest Diagnostics Inc trades at $238.01 (market cap $26.21B), while NetEase Inc trades at $123.86 (market cap $82.75B). The key difference: NetEase Inc is far larger — about 3.2× Quest Diagnostics Inc's market cap, and NetEase Inc pays the higher dividend (2.36%). Which is the better fit depends on your goals.
| DGX | NTES | |
|---|---|---|
Market Cap | $26.21B | $82.75B |
Sector | Health | Media |
52-Week High | $238.50 | $159.34 |
52-Week Low | $173.49 | $109.26 |
Enterprise Value | $31.97B | $59.05B |
Dividend Yield | 1.45% | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
NetEase (NTES) trades at $133.41, up 0.9% with bullish technical signals and strong fundamentals. The stock shows robust profitability with 29.84% net margins and 22.12% ROE, supported by consistent revenue growth to $112.63B in 2025. Recent Q1 2026 earnings beat expectations at $2.53 EPS versus $2.19 forecast. Technical analysis indicates bullish momentum with support at $131 and resistance at $135, while analyst consensus remains strongly positive with 82% buy ratings.
Outlook remains favorable given strong cash flow generation ($50.74B operating cash flow) and international expansion potential. Key risks include Chinese regulatory environment and competitive pressures. With attractive valuation at 16.31 P/E and bullish institutional sentiment, NTES presents growth opportunity though investors should monitor earnings consistency and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
